🟠 Moderate Evidence
The MTHFR gene has become ubiquitous in wellness discourse, with most attention focused on methylfolate supplementation in carriers of the C677T TT variant. However, clinical trial evidence points to an overlooked cofactor: riboflavin (vitamin B2), which the enzyme requires to function. Research from Ulster University demonstrates that riboflavin supplementation at near-dietary doses produces genotype-specific blood pressure reductions in TT carriers with hypertension—an effect sustained over four years.
Key takeaways
- Approximately 10% of European and US populations carry the MTHFR C677T TT variant, which produces a thermolabile enzyme prone to losing its FAD cofactor (derived from riboflavin)
- Riboflavin supplementation at 1.6 mg daily reduced systolic blood pressure by 13 mmHg in hypertensive TT carriers—from 144 to 131 mmHg over 16 weeks—with effects sustained over 4 years
- Only 37% of TT carriers on antihypertensive medication reached target blood pressure, compared to 64% of CC carriers; riboflavin closed this treatment-resistant gap
- The intervention dose is near the recommended dietary allowance (1.1–1.3 mg daily), not a megadose, raising questions about riboflavin deficiency in this population
Study at a Glance
| Primary evidence | Horigan et al., genotype-stratified RCT |
| Study type | Randomised controlled trial, genotype-prescreened |
| Intervention | Riboflavin 1.6 mg daily for 16 weeks |
| Primary population | Hypertensive patients with CVD, prescreened for MTHFR C677T genotype |
| Countries | United Kingdom (Ulster University) |
Blood Pressure Response to Riboflavin by MTHFR Genotype
Systolic BP change (mmHg) in hypertensive patients after 16 weeks of riboflavin 1.6 mg/day, stratified by C677T variant carrier status
Source: Horigan et al. (genotype-stratified trial) | GMJ News
The enzyme, the cofactor, and the gap in the narrative
MTHFR is an enzyme that catalyses the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate. This reaction is essential for methylation reactions throughout the body. The enzyme requires a cofactor called flavin adenine dinucleotide (FAD), which the body synthesises from riboflavin (vitamin B2). The C677T TT variant, present in approximately 10% of European and North American populations, produces a thermolabile version of the enzyme that loses FAD more readily than the wild-type variant, particularly under thermal stress.
This biochemical mechanism has been well-characterised. Yet the dominant wellness narrative has centred on methylfolate supplementation, largely overlooking the cofactor that makes the enzyme function. The clinical evidence, however, suggests that riboflavin—the precursor to FAD—may be the more effective intervention for TT carriers with hypertension.
Genotype-specific blood pressure reduction in a 16-week trial
In a randomised controlled trial by Horigan and colleagues at Ulster University, hypertensive patients with established cardiovascular disease were prescreened by MTHFR C677T genotype and randomly assigned to riboflavin 1.6 mg daily or placebo for 16 weeks. The results were sharply genotype-specific: TT carriers receiving riboflavin showed a 13 mmHg reduction in systolic blood pressure, from 144 to 131 mmHg. CC and CT carriers showed no significant change, indicating that the effect was confined to the homozygous variant carriers.
In hypertensive patients with the MTHFR C677T TT variant, riboflavin 1.6 mg daily reduced systolic blood pressure by 13 mmHg over 16 weeks, whereas CC and CT carriers showed no response—a genotype-specific effect consistent with cofactor deficiency.
— Horigan et al., Ulster University (genotype-stratified RCT)
The magnitude of this reduction is clinically relevant. Among TT carriers on antihypertensive medication at baseline, only 37% achieved target blood pressure (
Four-year sustainability and mechanism consolidation
Wilson and colleagues, also at Ulster University, followed the original cohort for four years with continued riboflavin supplementation, demonstrating that the blood pressure reduction was sustained over time. A separate RCT by the same group in hypertensive patients without overt cardiovascular disease confirmed the BP-lowering effect, broadening the applicability beyond the initial CVD-prescreened population.
The mechanistic basis is coherent: FAD depletion in TT carriers reduces MTHFR activity, leading to elevated homocysteine (a known vascular risk factor) and reduced methylation capacity. At the dose used in these trials—1.6 mg daily—riboflavin sits just above the recommended dietary allowance (RDA: 1.1–1.3 mg), suggesting that many TT carriers may operate at subclinical riboflavin insufficiency. This is not a megadose intervention; it is essentially cofactor replacement at near-physiological levels.
The replication challenge and clinical implications
A significant limitation of the current evidence is that nearly all published trials come from a single research group at Ulster University. While the individual trial methodology is rigorous and the mechanism well-characterised, independent replication from other institutions would substantially strengthen confidence in the findings. The genotype-specific response pattern is internally consistent and biologically plausible, but larger multicentre trials remain absent from the literature.
Despite this limitation, the clinical signal is clear enough to warrant clinical consideration, particularly in TT carriers with treatment-resistant hypertension. Standard antihypertensive agents remain first-line therapy, but the addition of low-dose riboflavin represents a simple, non-toxic, and inexpensive adjunctive intervention supported by mechanistic reasoning and genotype-specific evidence. The current narrative focus on methylfolate supplementation, while not harmful, may be masking the more actionable finding: that cofactor restoration—not folate saturation—is the key intervention for this population. For a fuller exploration of nutrient interactions and genetic variation, see our explainers section on nutrigenomics.
What this means
Frequently asked questions
Does everyone with the MTHFR C677T TT variant need riboflavin supplementation?
No. The blood pressure reduction was observed specifically in hypertensive TT carriers. Normotensive individuals with this variant do not require supplementation based on current evidence. The intervention is targeted to a specific clinical phenotype (hypertension) in a specific genotype.
Is 1.6 mg of riboflavin safe, and is it different from the RDA?
Yes, 1.6 mg is safe and only marginally higher than the RDA (1.1–1.3 mg daily). Riboflavin is water-soluble and non-toxic; excess amounts are excreted. This dose represents cofactor restoration, not a pharmacological megadose intervention. It can be obtained from food or supplementation.
Should I take methylfolate instead, or in addition to riboflavin?
The clinical evidence supports riboflavin for blood pressure control in TT carriers with hypertension. Methylfolate has not been shown to produce the same genotype-specific BP reduction. Folate supplementation remains important for other reasons (e.g., homocysteine reduction, pregnancy), but the two interventions are not interchangeable. Discuss with your clinician which supplementation approach is appropriate for your individual case.
The MTHFR variant story is far from complete. Independent replication of the riboflavin findings, investigation of other phenotypes (neurological, psychiatric, fertility), and mechanistic studies in larger populations are needed to move this from a single-group finding to standard precision medicine practice. However, for clinicians caring for hypertensive TT carriers, the current evidence is sufficient to consider this simple intervention, and for researchers, it is sufficient to prioritise replication as a high-value clinical question.
Source: MTHFR is one of the most discussed genes in the wellness space
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Editorial standards. This article was produced under the GMJ News editorial process, with oversight by the GMJ Editorial Board. Our editorial process. Spotted an error? Contact the editorial team.
